LES Foundation | LESI | Print Page | Contact Us | Sign In | Join
Growth and Diversification of a Specialty Pharmaceutical Company through Licensing and M&A
Tell a Friend About This EventTell a Friend
 

LES Research Triangle Park Chapter Meeting

4/14/2015
When: Tuesday, April 14, 2015
11:45 am – 1:30 pm
Where: Maggiano’s Little Italy The Streets at SouthPoint
8030 Renaissance Parkway
Suite 890
Durham, North Carolina  27713
United States

« Go to Upcoming Event List  

DATE & TIME
Tuesday, April 14, 2015
11:45 am – 1:30 pm

LOCATION
Maggiano's Little Italy
The Streets at SouthPoint
8030 Renaissance Parkway Suite 890
Durham, NC 27713
www.maggianos.com

TITLE
Growth and Diversification of a Specialty Pharmaceutical Company through Licensing and M&A

SPEAKER
Dr. Sarah Caley, Associate Director of Business Development, Merz North America

DESCRIPTION
Merz North America is the US/Canadian subsidiary of Merz Pharmaceuticals GmbH – a 107 year old, privately held German Specialty Pharmaceutical company with a deep tradition in aesthetics and neurology.   The North American business has undergone unparalleled growth over the last five years.  We will discuss the strategy behind this growth, including some highlights of interesting deals and transactions, as well as the challenges faced by a private specialty pharma company competing against large pharma players.

SCHEDULE
11:45 AM – 12:00 PM Registration, Networking and Appetizers
12:00 PM – 1:30 PM Lunch and Speaker

REGISTRATION
Early by April 1, 2015
LES Members: $35
Non-Members: $40

Regular & Onsite
LES Members: $40
Non-Members: $45

Please note that space is limited, so please register early and note that onsite registration will be subject to available seating.

Online Registration Deadline: April 13, 2015, 12 PM EDT

CANCELLATION POLICY
No refunds after Monday, April 13, 2015
Substitutions are permitted

SPEAKER BIO
Sarah Caley has been with Merz North America for over four years where she has functional responsibility for business development activities for all five business units (Aesthetics, Neurology, Medical Dermatology, Cosmeceuticals, and Energy Devices) in North America.  Prior to Merz, she spent nearly 10 years in Business Development/Licensing with AlphaVax, having worked on the core platform technology during her doctoral work in the Department of Microbiology and Immunology, UNC – Chapel Hill School of Medicine.